Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.4
3.9
Journals
JCM
Special Issues
Rheumatoid Arthritis: Pathogenesis, Diagnosis and Therapies—Part II
share announcement

Rheumatoid Arthritis: Pathogenesis, Diagnosis and Therapies—Part II

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Immunology".

Deadline for manuscript submissions: closed (20 February 2023) | Viewed by 7567

Special Issue Editor

Prof. Dr. Vincent Goeb

E-Mail Website
Guest Editor
Rheumatology Department, University Hospital of Amiens, University of Picardie-Jules Verne, Amiens, France
Interests: rheumatoid arthritis; biomarkers; biologics; ankylosing spondylitis; robot-assisted biopsy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

In 2022, rheumatoid arthritis (RA) is still the most common chronic inflammatory rheumatism in adults. Despite considerable progress in its early diagnosis thanks to the contribution of immunology and imaging, and in particular osteoarticular ultrasound, questions persist about the initial pathophysiological mechanisms leading to this inflammatory and autoimmune pathology. The concept of a triggering event occurring in a genetically predisposed individual living in a favorable environment (tobacco, pollution, etc.) is still topical, but deserves further study.

Treatments for RA have seen significant innovations (a real RAvolution!), and anti-TNFs are no longer the only biological DMARDs capable of providing long-lasting treatment for this disease. Unfortunately, RA is still dreadful because of the bone and joint damage that it can cause, leading to permanent disability that dramatically alters the quality of life of patients. The JAKi have brought a renewal in therapy, but their current reassessment by the EMA (PRAC) raises questions.

With all these elements, we invite you to submit your work on the pathophysiology, diagnostic methods, and your therapeutic experiences as well as strategies in RA in order to publish them in this Special Issue of the Journal of Clinical Medicine.

To your keyboards, we look forward to hearing from you!

Prof. Dr. Vincent Goeb
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • rheumatoid arthritis
  • biomarkers
  • imaging
  • biologics
  • strategy
  • cytokines
  • JAK inhibitors
  • comorbidities
  • patient-reported outcomes
  • educational program

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

16 pages, 1135 KiB  
Article
The Interaction Effect of Anti-RgpA and Anti-PPAD Antibody Titers: An Indicator for Rheumatoid Arthritis Diagnosis
by Diana Marcela Castillo, Gloria Inés Lafaurie, Consuelo Romero-Sánchez, Nathaly Andrea Delgadillo, Yormaris Castillo, Wilson Bautista-Molano, César Pacheco-Tena, Juan Manuel Bello-Gualtero, Philippe Chalem-Choueka and Jaime E. Castellanos
J. Clin. Med. 2023, 12(8), 3027; https://0-doi-org.brum.beds.ac.uk/10.3390/jcm12083027 - 21 Apr 2023
Cited by 2 | Viewed by 1611
Abstract
Porphyromonas gingivalis secretes virulence factors like Arg-gingipains and peptidyl arginine deiminase (PPAD), that are associated with rheumatoid arthritis (RA) pathogenesis. However, there is no information regarding the antibody titers for these bacterial enzymes as systemic indicators or biomarkers in RA. In this cross-sectional [...] Read more.
Porphyromonas gingivalis secretes virulence factors like Arg-gingipains and peptidyl arginine deiminase (PPAD), that are associated with rheumatoid arthritis (RA) pathogenesis. However, there is no information regarding the antibody titers for these bacterial enzymes as systemic indicators or biomarkers in RA. In this cross-sectional study, 255 individuals were evaluated: 143 were diagnosed with RA, and 112 were without RA. Logistic regression models adjusted for age, sex, basal metabolic index, smoking, and periodontitis severity were used to evaluate the association of RA with rheumatoid factor (RF), anti-citrullinated protein antibodies (ACPAs), erythrocyte sedimentation rate, high sensitivity C-reactive protein, anti-RgpA, anti-PPAD, and double positive anti-RgpA/anti-PPAD. It was found that RF (odds ratio [OR] 10.6; 95% confidence interval [CI] 4.4–25), ACPAs (OR 13.7; 95% CI 5.1–35), and anti-RgpA/anti-PPAD double positivity (OR 6.63; 95% CI 1.61–27) were associated with RA diagnoses. Anti-RgpA was also associated with RA (OR 4.09; 95% CI 1.2–13.9). The combination of anti-RgpA/anti-PPAD showed a high specificity of 93.7% and 82.5% PPV in identifying individuals with RA. RgpA antibodies were associated with the periodontal inflammatory index in RA individuals (p < 0.05). The double positivity of the anti-RgpA/anti-PPAD antibodies enhanced the diagnosis of RA. Therefore, RgpA antibodies and anti-RgpA/anti-PPAD may be biomarkers for RA. Full article
(This article belongs to the Special Issue Rheumatoid Arthritis: Pathogenesis, Diagnosis and Therapies—Part II)
►▼ Show Figures

Figure 1

11 pages, 2002 KiB  
Article
CD8+ Regulatory T Cell Deficiency in Elderly-Onset Rheumatoid Arthritis
by Ryu Watanabe, Keiichiro Kadoba, Atsuko Tamamoto, Koichi Murata, Kosaku Murakami, Hideo Onizawa, Takayuki Fujii, Akira Onishi, Masao Tanaka, Hiromu Ito, Akio Morinobu and Motomu Hashimoto
J. Clin. Med. 2023, 12(6), 2342; https://0-doi-org.brum.beds.ac.uk/10.3390/jcm12062342 - 17 Mar 2023
Cited by 5 | Viewed by 1999
Abstract
Elderly-onset rheumatoid arthritis (EORA) is associated with higher disease activity and accelerated joint destruction compared with young-onset RA (YORA). However, the underlying immunological mechanism remains unclear. Regulatory T cells (Tregs) are an immunosuppressive T cell subset, and CD4+ Tregs are deficient and/or [...] Read more.
Elderly-onset rheumatoid arthritis (EORA) is associated with higher disease activity and accelerated joint destruction compared with young-onset RA (YORA). However, the underlying immunological mechanism remains unclear. Regulatory T cells (Tregs) are an immunosuppressive T cell subset, and CD4+ Tregs are deficient and/or dysfunctional in RA; however, CD8+ Tregs have not been fully examined in RA. Here, we aimed to determine the role of CD8+ Tregs, particularly in EORA. A total of 40 patients (EORA, n = 17; YORA, n = 23) were cross-sectionally enrolled. Current disease activity and treatment were comparable between the two groups; however, levels of multiple cytokines, including IL-1β, TNFα, interferon (IFN)-γ, IL-2, and IL-10, were significantly increased in EORA. The number of CD4+ Tregs did not differ between the groups (p = 0.37), but those of CD8+ Tregs were significantly decreased in EORA (p = 0.0033). The number of CD8+ Tregs were inversely correlated with plasma matrix metalloprotease (MMP)-3 levels (r = −0.3331, p = 0.036). Our study results revealed an intrinsic deficiency of CD8+ Tregs in patients with EORA, which leaves synovitis unchecked with excessive MMP-3 release. A therapeutic approach to restore CD8+ Tregs may provide a new avenue for the treatment of EORA. Full article
(This article belongs to the Special Issue Rheumatoid Arthritis: Pathogenesis, Diagnosis and Therapies—Part II)
►▼ Show Figures

Figure 1

11 pages, 674 KiB  
Article
Is the Calcium Score Useful for Rheumatoid Arthritis Patients at Low or Intermediate Cardiovascular Risk?
by Claire Jesson, Yohann Bohbot, Simon Soudet, Cedric Renard, Jean-Marc Sobhy Danial, Laetitia Diep, Marie Doussière, Christophe Tribouilloy and Vincent Goëb
J. Clin. Med. 2022, 11(16), 4841; https://0-doi-org.brum.beds.ac.uk/10.3390/jcm11164841 - 18 Aug 2022
Cited by 3 | Viewed by 1404
Abstract
Cardiovascular disease, particularly myocardial infarction, is the leading cause of death of rheumatoid arthritis (RA) patients. The usefulness of the coronary artery calcification score (CACS), determined using cardiac computed-tomography (CT)-scan images, was assessed as a part of a cardiovascular work-up of RA patients [...] Read more.
Cardiovascular disease, particularly myocardial infarction, is the leading cause of death of rheumatoid arthritis (RA) patients. The usefulness of the coronary artery calcification score (CACS), determined using cardiac computed-tomography (CT)-scan images, was assessed as a part of a cardiovascular work-up of RA patients at low or intermediate cardiovascular disease risk. This descriptive, cross-sectional, single-center study was conducted on patients with stable RA or that which is in remission. Each patient’s work-up included a collection of cardiovascular risk factors, laboratory analyses, an electrocardiogram, a supra-aortic trunks (SATs) echo-Doppler test and a cardiac CT scan. The primary endpoint was to determine the frequency of patients with a CACS > 100, indicating notable atherosclerosis. Fifty patients were analyzed: mean ± standard deviation age was 53.7 ± 7.5 years, 82% women. The CACS exceeded 100 in 12 (24%) patients (11 were at intermediate risk) and 2 of them underwent angioplasty for silent myocardial ischemia. Cardiovascular risk was reclassified from intermediate to high for 5 patients. Age according to sex and smoking status were significantly associated with that increase; no association was found with RA characteristics or treatments. Full article
(This article belongs to the Special Issue Rheumatoid Arthritis: Pathogenesis, Diagnosis and Therapies—Part II)
►▼ Show Figures

Figure 1

Other

Jump to: Research

11 pages, 308 KiB  
Brief Report
Surgical Treatment of Juvenile Idiopathic Arthritis in the Era of Novel Drug Therapies
by Céline Klein, Vincent Barbier, Christophe Glorion and Richard Gouron
J. Clin. Med. 2023, 12(10), 3402; https://0-doi-org.brum.beds.ac.uk/10.3390/jcm12103402 - 11 May 2023
Viewed by 1744
Abstract
Juvenile idiopathic arthritis is the most common chronic rheumatic disease encountered in children under the age of sixteen and causes significant impairments in daily life. Over the last two decades, the introduction of new drug treatments (including disease-modifying antirheumatic drugs and biologics) has [...] Read more.
Juvenile idiopathic arthritis is the most common chronic rheumatic disease encountered in children under the age of sixteen and causes significant impairments in daily life. Over the last two decades, the introduction of new drug treatments (including disease-modifying antirheumatic drugs and biologics) has changed the course of this disease, thus reducing the indication for surgery. However, some patients fail to respond to drug therapy and thus require personalized surgical management, e.g., the local reduction of joint effusion or a synovial pannus (via intra-articular corticosteroid injections, synovectomy, or soft tissue release), and management of the sequelae of arthritis (such as growth disorders and joint degeneration). Here, we provide an overview of the surgical indications and outcomes of the following interventions: intra-articular corticosteroid injections, synovectomy, soft tissue release, surgery for growth disorders, and arthroplasty. Full article
(This article belongs to the Special Issue Rheumatoid Arthritis: Pathogenesis, Diagnosis and Therapies—Part II)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop